Abstract
Dysregulation of glutamate signalling is important in Alzheimer's disease and other pathologies. There has been a focus on changes in neuronal glutamate signalling, but microglia also express glutamate receptors (GluRs), which are known to modulate their responses to neuropathology. Microglia express both metabotropic and ionotropic GluRs. Among ionotropic GluRs, microglial AMPA (α-amino-hydroxy-5-methyl-isoxazole-4-propionate)-type of GluRs (AMPA-Rs) are Ca2+ impermeable due to the expression of subunit GluA2. Upon activation of microglia, expression level of surface GluA2 subunits significantly increase, while expression of GluA1, A3 and A4 subunits on membrane surface significantly decrease. Owing to the GluA2 subunits-dominant composition, AMPA-Rs in activated microglia show little response to Glu. On the other hand, microglia lacking GluA2 show higher Ca2+-permeability, consequently inducing a significant increase in the release of the pro-inflammatory cytokine, such as TNF-α. It is suggested that membrane translocation of GluA2-containing AMPA-Rs in activated microglia has functional importance. Thus, dysfunction or decreased expression of GluA2 reported in patients with neurodegenerative diseases such as Alzheimer’s and Creutzfeldt-Jakob disease may accelerate Glu neurotoxicity via excess release of proinflammatory cytokines from microglia, causing more neuronal death.
Keywords: AMPA receptor, GluA2, Ca2+ permeability, microglia, neurodegeneration, TNF-α.
Current Alzheimer Research
Title:Dysfunction of Glutamate Receptors in Microglia May Cause Neurodegeneration
Volume: 13 Issue: 4
Author(s): Mami Noda
Affiliation:
Keywords: AMPA receptor, GluA2, Ca2+ permeability, microglia, neurodegeneration, TNF-α.
Abstract: Dysregulation of glutamate signalling is important in Alzheimer's disease and other pathologies. There has been a focus on changes in neuronal glutamate signalling, but microglia also express glutamate receptors (GluRs), which are known to modulate their responses to neuropathology. Microglia express both metabotropic and ionotropic GluRs. Among ionotropic GluRs, microglial AMPA (α-amino-hydroxy-5-methyl-isoxazole-4-propionate)-type of GluRs (AMPA-Rs) are Ca2+ impermeable due to the expression of subunit GluA2. Upon activation of microglia, expression level of surface GluA2 subunits significantly increase, while expression of GluA1, A3 and A4 subunits on membrane surface significantly decrease. Owing to the GluA2 subunits-dominant composition, AMPA-Rs in activated microglia show little response to Glu. On the other hand, microglia lacking GluA2 show higher Ca2+-permeability, consequently inducing a significant increase in the release of the pro-inflammatory cytokine, such as TNF-α. It is suggested that membrane translocation of GluA2-containing AMPA-Rs in activated microglia has functional importance. Thus, dysfunction or decreased expression of GluA2 reported in patients with neurodegenerative diseases such as Alzheimer’s and Creutzfeldt-Jakob disease may accelerate Glu neurotoxicity via excess release of proinflammatory cytokines from microglia, causing more neuronal death.
Export Options
About this article
Cite this article as:
Noda Mami, Dysfunction of Glutamate Receptors in Microglia May Cause Neurodegeneration, Current Alzheimer Research 2016; 13 (4) . https://dx.doi.org/10.2174/1567205013666151116125810
DOI https://dx.doi.org/10.2174/1567205013666151116125810 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microglia Phenotype Diversity
CNS & Neurological Disorders - Drug Targets Regulation of Gene Expression by TDP-43 and FUS/TLS in Frontotemporal Lobar Degeneration
Current Alzheimer Research Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer’s and Parkinson’s Disease
Current Drug Metabolism Polymerase Delta in Eukaryotes: How is It Transiently Exchanged with Specialized DNA Polymerases During Translesion DNA Synthesis?
Current Protein & Peptide Science Recent Developments in the Regulation of Monoamine Oxidase Form and Function: Is the Current Model Restricting Our Understanding of the Breadth of Contribution of Monoamine Oxidase to Brain [dys]Function?
Current Topics in Medicinal Chemistry Flavonoids in Neurodegeneration: Limitations and Strategies to Cross CNS Barriers
Current Medicinal Chemistry Behavioral Experimental Paradigms for the Evaluation of Drug’s Influence on Cognitive Functions: Interpretation of Associative, Spatial/Nonspatial and Working Memory
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Neurodegeneration, Oxidative Stress, Metabolic Syndrome, Drug Design and Development: Clinical Implications)
CNS & Neurological Disorders - Drug Targets Erythropoietin Signaling and Neuroprotection
Current Signal Transduction Therapy The Glial Sodium-Calcium Exchanger: A New Target for Nitric Oxide- Mediated Cellular Toxicity
Current Protein & Peptide Science Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Mitochondrial Biogenesis: A Therapeutic Target for Neurodevelopmental Disorders and Neurodegenerative Diseases
Current Pharmaceutical Design Immune Functions of Glia and Neurons in the Central Nervous System
Current Immunology Reviews (Discontinued) Cross Currents in Protein Misfolding Disorders: Interactions and Therapy
CNS & Neurological Disorders - Drug Targets Targeting Cancer and Neuropathy with Histone Deacetylase Inhibitors:Two Birds with One Stone?
Current Cancer Drug Targets Tau Pathology and Future Therapeutics
Current Alzheimer Research Commentary Research Highlights: Untangling Alzheimer Disease Pathology
CNS & Neurological Disorders - Drug Targets Melatonin Attenuates Methamphetamine-Induced Neurotoxicity
Current Pharmaceutical Design